All In Biotech

Drug Trial Radar · NCT03502668

Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)

Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

160

Actual

Start

Jul 27, 2018

Primary completion

Jan 13, 2026

Study completion Jan 13, 2026

Sponsor

Lead sponsor
Taiho Oncology, Inc.Industry
Sponsor type
Industry
First posted
Apr 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multicenter, open-label study of various ASTX727 LD doses and schedules to assess safety, pharmacodynamics, pharmacokinetics, and hematologic response in subjects with International Prognostic Scoring System (IPSS) risk category of low-risk or Intermediate-1 MDS. This study will be conducted in two phases. In phase 1 subjects will be randomized into 3 cohorts in a 28-day cycles. Phase 2, 80 new subjects will be randomized in a 1:1 ratio into 2 doses/schedules.

Conditions

  • Myelodysplastic Syndromes

Interventions

  • ASTX727 LDDrug

    oral decitabine (LD) + cedazuridine (E7727)

  • ASTX727 SDDrug

    oral decitabine (SD) + cedazuridine (E7727)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of drug-related Grade ≥3 Adverse Events (AEs) or dose-limiting toxicities (DLTs) (if any) for each cohort dose/scheduleTime frame: 18-24 months
  2. Hematologic response based on normalization of conversion of any baseline cytopenia or anemia (hemoglobin response, neutrophil response, platelet response, transfusion independence)Time frame: 18-24 months

Locations

29 sites in 6 countries. Site status is shown where the registry gives one.

  • The University of Alabama at Birmingham

    Birmingham, Alabama

  • University of Colorado, Anschutz Cancer Pavilion

    Aurora, Colorado

  • Yale Cancer Center

    New Haven, Connecticut

  • Mayo Clinic Florida

    Jacksonville, Florida

  • BRCR Medical Center Inc.

    Plantation, Florida

  • Moffitt Cancer Center Site#507

    Tampa, Florida

  • The University of Chicago

    Chicago, Illinois

  • Indiana University Health Hospital - Simon Cancer Center

    Indianapolis, Indiana

  • University of Kansas Clinical Research Center

    Westwood, Kansas

  • The Center for Cancer and Blood Disorders (RCCA MD LLC - Maryland Division)

    Bethesda, Maryland

  • Mayo Clinic

    Rochester, Minnesota

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York

  • Oregon Health and Science University Knight Cancer Institute

    Portland, Oregon

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Vanderbilt University Medical Center - Hematology-Oncology

    Nashville, Tennessee

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Texas Oncology - Tyler

    Tyler, Texas

  • ZNA - Campus Middelheim

    Antwerp, Belgium

  • Az St-Jan Brugge-Oostende A.V.

    Bruges, Belgium

  • University of Alberta Hospital - Hematology Research

    Edmonton, Canada

  • London Regional Cancer Center

    London, Ontario, Canada

  • Universitaetsklinikum Freiburg Site#703

    Freiburg im Breisgau, Germany

  • Universitätsklinikum Halle

    Halle, Germany

  • Universita degli Studi di Firenze

    Florence, Italy

  • Hospital Universitario Vall d Hebron

    Barcelona, Spain

  • Institut Català d'Oncologia Badalona Hospital Universitari Germans Trias i Pujol

    Barcelona, Spain

  • Hospital General Universitario Gregorio Marañón

    Madrid, Spain

  • Hospital Univeristario y Politecnico La Fe Servicio de Hematologia

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.